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Introduction {#sec005}
============

Tuberculosis (TB) has been considered a worldwide public health problem by the World Health Organization (WHO) since 1993, and global actions have been taken to control this disease \[[@pone.0160109.ref001],[@pone.0160109.ref002]\]. However, in recent years, epidemiological indicators have pointed to a low effectiveness of TB prevention and control activities in regions where HIV rates are high and where drug-resistant (DR), multidrug-resistant (MDR), or extensively drug-resistant (XDR) TB has been identified \[[@pone.0160109.ref003]--[@pone.0160109.ref005]\]. Cure rates of only 58% to 67% have been achieved in these settings, according to systematic reviews and meta-analyses \[[@pone.0160109.ref003]--[@pone.0160109.ref005]\].

Since the launch of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance in 1994 by WHO, a large volume of drug resistance data from several countries has been collected and analyzed \[[@pone.0160109.ref003]\]. However, drug resistance surveys have provided little information on clinical and laboratory outcomes after initiation of treatment in patients with a diagnosis of DR-TB or MDR-TB \[[@pone.0160109.ref006]\].

In Brazil, the effectiveness of TB control programs tends to be lower in major cities. Preliminary data obtained from the II National Anti-Tuberculosis Drug Resistance Survey conducted between 2006 and 2007, involving 4,421 patients from seven states (Rio de Janeiro, Rio Grande do Sul, Bahia, Distrito Federal, Santa Catarina, Minas Gerais, and São Paulo), show rates of 1.4% (1.0--1.8) for primary MDR-TB and 7.5% (5.7--9.9) for acquired MDR-TB. In Porto Alegre, a large city and the capital of the Southern Brazilian state of Rio Grande do Sul, primary and acquired MDR-TB rates were higher than the national average at 2.2% and 12.0% respectively \[[@pone.0160109.ref007]\]. This rate for primary MDR-TB is also above the upper limit of 2% established by WHO \[[@pone.0160109.ref001]\]. In addition, high rates of TB and HIV co-infection (35.0%) and treatment default (19.6%) have also been reported in this geographical setting \[[@pone.0160109.ref008]\].

The purpose of this study was to evaluate the clinical features and treatment outcomes of DR-TB and MDR-TB cases in Porto Alegre, southern Brazil, as identified through the nationwide survey.

Methods {#sec006}
=======

This was a historical cohort study based on data from the II National Anti-Tuberculosis Drug Resistance Survey conducted in 2006 and 2007 in Brazil. We analyzed the data collected at the eight public health care facilities (five primary health care units and three hospitals) that participated in the survey in Porto Alegre. Porto Alegre is the capital of Rio Grande do Sul, the southernmost state of Brazil, and had a population of 1,415,237 inhabitants and a Human Development Index of 0.865 in 2007 \[[@pone.0160109.ref009]\]. This study was approved by the Porto Alegre Municipal Health Department Research Ethics Committee (protocol no. 001.053413.05.3). Written informed consent was obtained from all participants or a legally authorized representative prior to their inclusion in the study.

The II National Anti-Tuberculosis Drug Resistance Survey was performed by means of in-person standardized interviews conducted by trained interviewers, who used an instrument with pre-coded response categories \[[@pone.0160109.ref010]\].

Participant samples were analyzed by the Löwenstein--Jensen proportion method, in accordance with Brazilian National Tuberculosis Guidelines \[[@pone.0160109.ref008]\]. All clinical samples were sent to the Rio Grande do Sul State Referral Laboratory for culture, drug susceptibility testing, and identification at the species level. Tests were performed as per standard laboratory procedures; the techniques employed are described elsewhere \[[@pone.0160109.ref011], [@pone.0160109.ref012]\]. Smears were stained by the Ziehl--Neelsen method at the local Mycobacteriology Laboratory and scored as per international guidelines. All laboratories involved in testing used a double-blinded method for internal quality control. In addition, all samples identified as drug-resistant were retested by another referral laboratory, as were 15% of those identified as susceptible.

WHO definitions of drug sensitivity and drug resistance were used. Namely, DS-TB was defined as TB caused by strains of *Mycobacterium tuberculosis* that are sensitive to any anti-TB drug; DR-TB, as TB caused by strains that are resistant to at least one drug; monoresistant TB, as TB caused by strains that are resistant to one drug; and MDR-TB, as TB caused by strains of *M*. *tuberculosis* that are resistant to at least isoniazid and rifampicin \[[@pone.0160109.ref001]\].

A total of 299 TB patients with DR-TB or MDR-TB were identified at the participating public health care facilities in Porto Alegre. Of these, 216 (72.2%) cases were diagnosed at five public primary health care units and 83 (27.8%) at three public hospitals. Patient care during the study did not deviate from routine procedures.

The following variables collected during the nationwide survey were analyzed in the present study: sociodemographic characteristics, clinical features, comorbidities, and clinical and laboratory results during anti-TB treatment. Race/Ethnicity was self-reported according to the five Brazilian census categories (white, black, yellow, brown, or indigenous) \[[@pone.0160109.ref013]\] and, for the purposes of this study, was classified as white, African descent, east Asian descent, Mixed race (those with mixed racial ancestry, known as pardos), and Indigenous descent, as described elsewhere \[[@pone.0160109.ref014]\].

The cohort was followed for 3 years after the initiation of anti-TB treatment, using three sources of data: (*a*) medical records of patients participating in the Municipal TB Control Program; (*b*) Brazilian Ministry of Health information systems--the Notifiable Diseases Information System (SINAN) for TB and AIDS notification, the Mortality Information System (SIM), the Central Public Health Laboratory of Rio Grande do Sul, and the MDR-TB Information System; and (*c*) medical records of patients at the health care facilities where they were treated or monitored.

The following steps were performed for data search: (*i*) identification of the records of all 299 patients in the national database generated from the SINAN TB and AIDS databases; (*ii*) identification of the medical records of all patients in the Municipal TB Control Program and at the health care facilities where they were treated or monitored; and (*iii*) identification of the records of all patients in databases generated from the Mortality Information System, the Central Public Health Laboratory, and the MDR-TB Information System.

Data on smoking, alcohol consumption, and illicit drug use were extracted from patients' medical records, and were not necessarily obtained from validated instruments. Clinical and laboratory monitoring data and anti-TB treatment results were extracted primarily from the SINAN databases. In some cases, however, these data were available only in the MDR-TB Information System or in patients' records at reference facilities, such as the Outpatient Clinic at Hospital Sanatório Partenon, which is the center of excellence for treatment of DR-TB and MDR-TB in Porto Alegre.

According to Brazilian Ministry of Health guidelines on TB control, sputum smear microscopy should be performed monthly to monitor anti-TB treatment \[[@pone.0160109.ref011]\]. However, some cases were missing data on monthly smear results in the records or other information sources used. In these cases, because it was our intention to identify the month in which the patient's sputum converted to negative, the sputum smear result from the following month was imputed to fill in for the missing value. In addition, because patients are unlikely to become positive after converting to negative, whenever a positive result was both preceded and followed by a negative result, this result was replaced with a negative result, as it was considered a possible human error in filling out the information. Thus, we sought to ensure a non-biased estimate of the main result of this evaluation regardless of the month of the negative result.

We checked the SINAN databases for data entered up to December 2010 in order to verify the occurrence of new (previously untreated) and relapse (previously treated) TB cases. TB relapse was defined as a patient who had become (and remained) negative while receiving treatment, but became smear-positive again after completion of treatment \[[@pone.0160109.ref011]\].

A database was created for the purposes of this study using EpiData 3.1 (EpiData Association, Odense, Denmark). Statistical analysis included the calculation of prevalence estimates, 95% confidence intervals, and group comparisons (resistant vs. non-resistant). Parametric and nonparametric analysis of longitudinal data (clinical and laboratory monitoring data of treated TB cases) was performed using Stata 10 (StataCorp LP, College Station, TX, USA). Values were considered statistically significant if *p* \< 0.05.

Results {#sec007}
=======

A total of 299 cases of smear-positive pulmonary TB were included in the study. Among these cases, the prevalence of DR-TB, monoresistant TB, and MDR-TB was 14.4%, 8.4%, and 4.7% respectively. Additionally, 32.0% of previously treated patients had DR-TB (24/75), 18.7% had monoresistant TB (14/75), and 12.0% had MDR-TB (9/75) ([Table 1](#pone.0160109.t001){ref-type="table"}).

10.1371/journal.pone.0160109.t001

###### Level of drug resistance of patients with pulmonary TB identified through the II National Anti-TB Drug Resistance Survey (2006--2007), Porto Alegre, southern Brazil (*n* = 299).

![](pone.0160109.t001){#pone.0160109.t001g}

  Previous treatment   No resistance   Resistance                                                                                                 
  -------------------- --------------- ------------ -------------- ---- ------ -------------- ---- ------ ------------- ---- ------ ------------- -----
      Yes              51              68.0         (57.2--78.8)   24   32.0   (21.2--42.8)   14   18.7   (9.6--27.7)   9    12.0   (4.5--19.5)   75
      No               205             91.5         (87.9--95.2)   19   8.5    (4.8--12.1)    11   4.9    (2.0--7.8)    5    2.2    (0.3--4.2)    224
  Total                256             85.6         (87.9--95.2)   43   14.4   (10.4--18.4)   25   8.4    (5.2--11.5)   14   4.7    (2.3--7.1)    299

DR-TB, drug-resistant tuberculosis; MDR-TB, multidrug-resistant tuberculosis; TB, tuberculosis.

Sociodemographic characteristics for the overall sample and stratified by level of drug resistance are described in [Table 2](#pone.0160109.t002){ref-type="table"}. Most patients were white (62.3%) men (72.6%) aged 25 to 45 years (49.5%), with less than 8 years of education (72.1%). There was no association between DR-TB, monoresistant TB or MDR-TB status and sociodemographic variables (*p* = 0.05).

10.1371/journal.pone.0160109.t002

###### Sociodemographic characteristics of the study sample, stratified by level of anti-TB drug resistance, Porto Alegre, southern Brazil (2006--2007) (*n* = 299).

![](pone.0160109.t002){#pone.0160109.t002g}

  Characteristics        No resistance   Resistance                                                                                                                
  ---------------------- --------------- ------------ -------------- ---- ------ -------------- ---- ------ -------------- ---- ------ -------------- ----- ------ --------------
  Sex                                                                                                                                                              
      Male               188             73.4         (64.8--82.1)   29   67.4   (53.4--81.4)   11   64.7   (42--87.4)     10   71.4   (47.8--95.1)   217   72.6   (67.5--77.6)
      Female             68              26.6         (17.9--35.2)   14   32.6   (18.6--46.6)   6    35.3   (12.6--58)     4    28.6   (4.9--52.2)    82    27.4   (22.4--32.5)
  Age, years                                                                                                                                                       
      18 to 25           53              20.8         (12.8--28.7)   6    14.0   (7.2--20.7)    2    11.8   (5.4--18.1)    3    21.4   (13.4--29.5)   59    19.8   (12--27.6)
      26 to 35           73              28.6         (23.1--37.5)   10   23.3   (10.6--31.5)   3    17.6   (0--25.1)      3    21.4   (0--29.5)      83    27.9   (22.8--36.6)
      36 to 45           53              20.8         (15.8--25.8)   12   27.9   (14.5--41.3)   5    29.4   (7.8--51.1)    5    35.7   (10.6--60.8)   65    21.8   (17.1--26.5)
      46 to 55           51              20.0         (15.1--24.9)   9    20.9   (8.8--33.1)    4    23.5   (3.4--43.7)    2    14.3   (0--32.6)      60    20.1   (15.6--24.7)
      56 to 65           14              5.5          (2.7--8.3)     6    14.0   (3.6--24.3)    3    17.6   (0--35.8)      1    7.1    (0--20.6)      20    6.7    (3.9--9.6)
      66 to 75           7               2.7          (0.7--4.8)     0    0.0    (0--0)         0    0.0    (0--0)         0    0.0    (0--0)         7     2.3    (0.6--4.1)
      76 to 90           4               1.6          (0--3.1)       0    0.0    (0--0)         0    0.0    (0--0)         0    0.0    (0--0)         4     1.3    (0--2.6)
      Not reported       1               --           --             0    --     --             0    --     --             0    --     --             1     --     --
  Race/Ethnicity                                                                                                                                                   
      White              148             61.9         (55.8--68.1)   27   64.3   (49.8--78.8)   14   82.4   (64.2--100)    6    46.2   (19.1--73.3)   175   62.3   (56.6--67.9)
      African descent    64              26.8         (21.2--32.4)   13   31.0   (17--44.9)     2    11.8   (0--27.1)      7    53.8   (26.7--80.9)   77    27.4   (22.2--32.6)
      Mixed              26              10.9         (6.9--14.8)    2    4.8    (0--11.2)      1    5.9    (0--17.1)      0    0.0    (0--0)         28    10.0   (6.5--13.5)
      Asian descent      1               0.4          (0--1.2)       0    0.0    (0--0)         0    0.0    (0--0)         0    0.0    (0--0)         1     0.4    (0--1.1)
      Not reported       17              --           --             1    --     --             0    --     --             1    --     --             18    --     --
  Level of education                                                                                                                                               
      None               14              5.9          (2.9--8.9)     2    4.8    (0--11.2)      2    11.8   (0--27.1)      0    0.0    (0--0)         16    5.7    (3--8.4)
      1 to 3 years       49              20.6         (15.5--25.7)   7    16.7   (5.4--27.9)    4    23.5   (3.4--43.7)    3    23.1   (0.2--46)      56    20.0   (15.3--24.7)
      4 to 7 years       108             45.4         (39.1--51.7)   22   52.4   (37.3--67.5)   9    52.9   (29.2--76.7)   5    38.5   (12--64.9)     130   46.4   (40.6--52.3)
      8 to 11 years      57              23.9         (18.5--29.4)   11   26.2   (12.9--39.5)   2    11.8   (0--27.1)      5    38.5   (12--64.9)     68    24.3   (19.3--29.3)
      12 years or more   10              4.2          (1.7--6.8)     0    0.0    (0--0)         0    0.0    (0--0)         0    0.0    (0--0)         10    3.6    (1.4--5.7)
      Not reported       18              --           --             1    --     --             0    --     --             1    --     --             19    --     --
  Institutionalization                                                                                                                                             
      No                 207             87.3         (83.1--91.6)   35   83.3   (72.1--94.6)   13   76.5   (56.3--96.6)   11   84.6   (65--100)      242   86.7   (82.8--90.7)
      Prison             10              4.2          (1.7--6.8)     2    4.8    (0--11.2)      1    5.9    (0--17.1)      0    0.0    (0--0)         12    4.3    (1.9--6.7)
      Nursing home       2               0.8          (0--2)         1    2.4    (0--7)         0    0.0    (0--0)         1    7.7    (0--22.2)      3     1.1    (0--2.3)
      Hospital           10              4.2          (1.7--6.8)     2    4.8    (0--11.2)      1    5.9    (0--17.1)      1    7.7    (0--22.2)      12    4.3    (1.9--6.7)
      Homeless           4               1.7          (0--3.3)       2    4.8    (0--11.2)      2    11.8   (0--27.1)      0    0.0    (0--0)         6     2.2    (0.4--3.9)
      Other              4               1.7          (0--3.3)       0    0.0    (0--0)         0    0.0    (0--0)         0    0.0    (0--0)         4     1.4    (0--2.8)
      Not reported       19              --           --             1    --     --             0    --     --             1    --     --             20    --     --
  Employment                                                                                                                                                       
      Not employed       17              11.9         (6.6--17.2)    4    13.8   (1.2--26.3)    2    18.2   (0--41)        1    12.5   (0--35.4)      21    12.2   (7.3--17.1)
      Informal           44              30.8         (23.2--38.3)   9    31.0   (14.2--47.9)   4    36.4   (7.9--64.8)    1    12.5   (0--35.4)      53    30.8   (23.9--37.7)
      Formal             82              57.3         (49.2--65.4)   16   55.2   (37.1--73.3)   5    45.5   (16--74.9)     6    75.0   (45--100)      98    57.0   (49.6--64.4)
      Not reported       113             --           --             14   --     --             6    --     --             6    --     --             127   --     --
  Alcoholism                                                                                                                                                       
      Yes                77              40.5         (33.5--47.5)   14   40.0   (23.8--56.2)   5    41.7   (13.8--69.6)   4    36.4   (7.9--64.8)    91    40.4   (34--46.9)
      No                 113             59.5         (52.5--66.5)   21   60.0   (43.8--76.2)   7    58.3   (30.4--86.2)   7    63.6   (35.2--92.1)   134   59.6   (53.1--66)
      Not reported       66              --           --             8    --     --             5    --     --             3    --     --             74    --     --
  Smoking                                                                                                                                                          
      Yes                108             55.7         (48.7--62.7)   17   51.5   (34.5--68.6)   6    50.0   (21.7--78.3)   6    60.0   (29.6--90.4)   125   55.1   (48.6--61.5)
      No                 86              44.3         (37.3--51.3)   16   48.5   (31.4--65.5)   6    50.0   (21.7--78.3)   4    40.0   (9.6--70.4)    102   44.9   (38.5--51.4)
      Not reported       62              --           --             10   --     --             5    --     --             4    --     --             72    --     --
  Illicit drug use                                                                                                                                                 
      Yes                46              25.0         (18.7--31.3)   10   34.5   (17.2--51.8)   3    33.3   (2.5--64.1)    5    50.0   (19--81)       56    26.3   (20.4--32.2)
      No                 138             75.0         (68.7--81.3)   19   65.5   (48.2--82.8)   6    66.7   (35.9--97.5)   5    50.0   (19--81)       157   73.7   (67.8--79.6)
      Not reported       72              --           --             14   --     --             8    --     --             4    --     --             86    --     --

DR-TB, drug-resistant tuberculosis; MDR-TB, multidrug-resistant tuberculosis; TB, tuberculosis.

^a^ Percentages were calculated using the number of reported cases (i.e., the total number of cases minus the number of unreported cases) as the denominator.

[Table 3](#pone.0160109.t003){ref-type="table"} shows patient clinical data for the sample as a whole and stratified by level of drug resistance. The most common signs and symptoms were productive cough (80.4%), weight loss (69.8%), and fever (41.3%). The most common comorbidity was HIV infection (26.2%), followed by diabetes mellitus (5.2%) ([Table 4](#pone.0160109.t004){ref-type="table"}). There was no association between clinical features and presence of comorbidities (*p* \> 0.05).

10.1371/journal.pone.0160109.t003

###### Clinical features of the study sample, stratified by level of anti-TB drug resistance, Porto Alegre, southern Brazil (2006--2007) (*n*  =  299).

![](pone.0160109.t003){#pone.0160109.t003g}

  Characteristics    No resistance   Resistance                                                                                                               
  ------------------ --------------- ------------ -------------- ---- ------ -------------- ---- ------ -------------- --- ------ -------------- ----- ------ --------------
  Dry cough                                                                                                                                                   
      No             189             94.0         (90.8--97.3)   32   94.1   (86.2--100)    14   93.3   (80.7--100)    9   90.0   (71.4--100)    221   94.0   (91--97.1)
      Yes            12              6.0          (2.7--9.2)     2    5.9    (0--13.8)      1    6.7    (0--19.3)      1   10.0   (0--28.6)      14    6.0    (2.9--9)
      Not reported   55              --           --             9    --     --             2    --     --             4   --     --             64    --     --
  Productive cough                                                                                                                                            
      No             36              17.9         (12.6--23.2)   10   29.4   (14.1--44.7)   4    26.7   (4.3--49)      4   40.0   (9.6--70.4)    46    19.6   (14.5--24.6)
      Yes            165             82.1         (76.8--87.4)   24   70.6   (55.3--85.9)   11   73.3   (51--95.7)     6   60.0   (29.6--90.4)   189   80.4   (75.4--85.5)
      Not reported   55              --           --             9    --     --             2    --     --             4   --     --             64    --     --
  Fatigue                                                                                                                                                     
      No             36              17.9         (12.6--23.2)   10   29.4   (14.1--44.7)   4    26.7   (4.3--49)      4   40.0   (9.6--70.4)    46    19.6   (14.5--24.6)
      Yes            165             82.1         (76.8--87.4)   24   70.6   (55.3--85.9)   11   73.3   (51--95.7)     6   60.0   (29.6--90.4)   189   80.4   (75.4--85.5)
      Not reported   55              --           --             9    --     --             2    --     --             4   --     --             64    --     --
  Fever                                                                                                                                                       
      No             117             58.2         (51.4--65)     21   61.8   (45.4--78.1)   8    53.3   (28.1--78.6)   6   60.0   (29.6--90.4)   138   58.7   (52.4--65)
      Yes            84              41.8         (35--48.6)     13   38.2   (21.9--54.6)   7    46.7   (21.4--71.9)   4   40.0   (9.6--70.4)    97    41.3   (35--47.6)
      Not reported   55              --           --             9    --     --             2    --     --             4   --     --             64    --     --
  Hemoptysis                                                                                                                                                  
      No             182             90.5         (86.5--94.6)   28   82.4   (69.5--95.2)   13   86.7   (69.5--100)    9   90.0   (71.4--100)    210   89.4   (85.4--93.3)
      Yes            19              9.5          (5.4--13.5)    6    17.6   (4.8--30.5)    2    13.3   (0--30.5)      1   10.0   (0--28.6)      25    10.6   (6.7--14.6)
      Not reported   55              --           --             9    --     --             2    --     --             4   --     --             64    --     --
  Chest pain                                                                                                                                                  
      No             166             82.6         (77.3--87.8)   31   91.2   (81.6--100)    14   93.3   (80.7--100)    8   80.0   (55.2--100)    197   83.8   (79.1--88.5)
      Yes            35              17.4         (12.2--22.7)   3    8.8    (0--18.4)      1    6.7    (0--19.3)      2   20.0   (0--44.8)      38    16.2   (11.5--20.9)
      Not reported   55              --           --             9    --     --             2    --     --             4   --     --             64    --     --
  Sweating                                                                                                                                                    
      No             166             82.6         (77.3--87.8)   31   91.2   (81.6--100)    14   93.3   (80.7--100)    8   80.0   (55.2--100)    197   83.8   (79.1--88.5)
      Yes            35              17.4         (12.2--22.7)   3    8.8    (0--18.4)      1    6.7    (0--19.3)      2   20.0   (0--44.8)      38    16.2   (11.5--20.9)
      Not reported   55              --           --             9    --     --             2    --     --             4   --     --             64    --     --
  Weight loss                                                                                                                                                 
      No             56              27.9         (21.7--34.1)   15   44.1   (27.4--60.8)   9    60.0   (35.2--84.8)   4   40.0   (9.6--70.4)    71    30.2   (24.3--36.1)
      Yes            145             72.1         (65.9--78.3)   19   55.9   (39.2--72.6)   6    40.0   (15.2--64.8)   6   60.0   (29.6--90.4)   164   69.8   (63.9--75.7)
      Not reported   55              --           --             9    --     --             2    --     --             4   --     --             64    --     --

DR-TB, drug-resistant tuberculosis; MDR-TB, multidrug-resistant tuberculosis; TB, tuberculosis.

^a^ Percentages were calculated using the number of reported cases (i.e., the total number of cases minus the number of unreported cases) as the denominator.

10.1371/journal.pone.0160109.t004

###### Comorbidities of the study sample stratified by level of anti-TB drug resistance, Porto Alegre, southern Brazil (2006--2007) (*n* = 299).

![](pone.0160109.t004){#pone.0160109.t004g}

  Comorbidities      No resistance   Resistance   Total                                                                                                         
  ------------------ --------------- ------------ -------------- ---- ------- ------------- ---- ------- ------------- ---- ------- -------------- ----- ------ --------------
  Diabetes                                                                                                                                                      
      No             220             95.2         (92.5--98)     36   92.3    (83.9--100)   15   93.8    (81.9--100)   11   100.0   (100--100)     256   94.8   (92.2--97.5)
      Yes            11              4.8          (2--7.5)       3    7.7     (0--16.1)     1    6.3     (0--18.1)     0    0.0     (0--0)         14    5.2    (2.5--7.8)
      Not reported   25              --           --             4    --      --            1    --      --            3    --      --             29    --     --
  Hypertension                                                                                                                                                  
      No             224             97.0         (94.8--99.2)   39   97.5    (92.7--100)   16   94.1    (82.9--100)   11   100.0   (100--100)     263   97.0   (95--99.1)
      Yes            7               3.0          (0.8--5.2)     1    2.5     (0--7.3)      1    5.9     (0--17.1)     0    0.0     (0--0)         8     3.0    (0.9--5)
      Not reported   25              --           --             3    --      --            0    --      --            3    --      --             28    --     --
  HIV                                                                                                                                                           
      No             156             72.9         (66.9--78.9)   30   78.9    (66--91.9)    13   81.3    (62.1--100)   7    70.0    (41.6--98.4)   186   73.8   (68.4--79.2)
      Yes            58              27.1         (21.1--33.1)   8    21.1    (8.1--34)     3    18.8    (0--37.9)     3    30.0    (1.6--58.4)    66    26.2   (20.8--31.6)
      Not reported   42              --           --             5    --      --            1    --      --            4    --      --             47    --     --
  Mental illness                                                                                                                                                
      No             228             98.3         (96.6--100)    40   100.0   (100--100)    17   100.0   (100--100)    11   100.0   (100--100)     268   98.5   (97.1--100)
      Yes            4               1.7          (0--3.4)       0    0.0     (0--0)        0    0.0     (0--0)        0    0.0     (0--0)         4     1.5    (0--2.9)
      Not reported   24              --           --             3    --      --            0    --      --            3    --      --             27    --     --
  CKD                                                                                                                                                           
      No             231             100.0        (100--100)     39   97.5    (92.7--100)   17   100.0   (100--100)    11   100.0   (100--100)     270   99.6   (98.9--100)
      Yes            0               0.0          (0--0)         1    2.5     (0--7.3)      0    0.0     (0--0)        0    0.0     (0--0)         1     0.4    (0--1.1)
      Not reported   25              --           --             3    --      --            0    --      --            3    --      --             28    --     --

CKD, chronic kidney disease; DR-TB, drug-resistant tuberculosis; MDR-TB, multidrug-resistant tuberculosis; TB, tuberculosis.

^a^ Percentages were calculated using the number of reported cases (i.e., the total number of cases minus the number of unreported cases) as the denominator.

[Table 5](#pone.0160109.t005){ref-type="table"} shows the results of clinical monitoring and anti-TB treatment outcomes for the sample as a whole and stratified by level of drug resistance. DR-TB and MDR-TB cases were significantly associated with occurrence of previously treated TB (*p* = 0.01). Overall, patients with DR-TB had worse clinical outcomes, as evaluated by laboratory tests, than patients with other levels of drug resistance ([Table 5](#pone.0160109.t005){ref-type="table"}). Regarding sputum smear results, conversion to negative occurred in 81% of cases, and 65% of these patients achieved conversion at 2 months of treatment ([Fig 1](#pone.0160109.g001){ref-type="fig"}). However, only 45% of DR-TB cases became negative at 2 months (*p* = 0.004).

![Monthly sputum conversion to negative in resistant vs. non-resistant tuberculosis (TB), Porto Alegre, Brazil (2006--2007).](pone.0160109.g001){#pone.0160109.g001}

10.1371/journal.pone.0160109.t005

###### Results of clinical monitoring and anti-TB treatment outcomes of the study sample, stratified by level of anti-TB drug resistance, Porto Alegre, southern Brazil (2006--2007) (*n* = 299).

![](pone.0160109.t005){#pone.0160109.t005g}

  Characteristics                                          No resistance   Resistance   Total                                                                                                          
  -------------------------------------------------------- --------------- ------------ -------------- ---- ------ -------------- ---- ------ --------------- ---- ------- -------------- ----- ------ --------------
  No. of previous treatments                                                                                                                                                                           
      One                                                  34              14.4         (9.9--18.9)    16   40.0   (24.1--55.9)   8    50.0   (22.5--77.5)    5    38.5    (7.8--69.0)    50    18.1   (13.5--22.7)
      Two                                                  3               1.3          (0.1--2.7)     3    7.5    (1.0--16.0)    0    0.0    (0.0--0.0)      3    23.1    (34.2--49.6)   6     2.2    (0.4--3.9)
      Three or more                                        9               3.8          (1.3--6.2)     2    5.0    (2.0--12.0)    1    6.3    (0.0--19.5)     1    7.7     (0.0--24.4)    11    4.0    (1.7--6.3)
      No treatment                                         190             80.5         (75.4--85.5)   19   47.5   (31.3--63.7)   7    43.8   (16.4--71.0)    4    30.8    (1.7--59.7)    209   75.7   (70.6--80.8)
      Not reported                                         20              --           --             3    --     --             1    --     --              1    --      --             23    --     --
  Time of sputum conversion to negative                                                                                                                                                                
      Month 1                                              47              27.5         (20.7--34.2)   6    21.4   (5.2--37.6)    2    22.2   (0.0--56.1)     1    10.0    (0.0--32.6)    53    26.6   (20.4--32.8)
      Month 2                                              61              35.7         (28.4--42.9)   7    25.0   (7.9--42.1)    2    22.2   (0.0--56.1)     4    40.0    (3.0--76.9)    68    34.2   (27.5--40.8)
      Month 3                                              14              8.2          (4.0--12.3)    2    7.1    (0.0--17.3)    1    11.1   (0.0--36.7)     1    10.0    (0.0--32.6)    16    8.0    (4.2--11.8)
      Month 4                                              11              6.4          (2.7--10.1)    0    0.0    (0.0--0.0)     0    0.0    (0.0--0.0)      0    0.0     (0.0--0.0)     11    5.5    (2.3--8.7)
      Month 5                                              6               3.5          (0.7--6.2)     0    0.0    (0.0--0.0)     0    0.0    (0.0--0.0)      0    0.0     (0.0--0.0)     6     3.0    (0.6--5.4)
      Month 6                                              8               4.7          (1.4--7.8)     0    0.0    (0.0--0.0)     0    0.0    (0.0--0.0)      0    0.0     (0.0--0.0)     8     4.0    (1.2--6.7)
      No conversion                                        24              14.0         (8.8--19.3)    13   46.4   (26.7--66.1)   4    44.4   (3.9--84.9)     4    40.0    (3.0--76.9)    37    18.6   (13.1--24.0)
      Not reported                                         85              --           --             15   --     --             8    --     --              4    --      --             100   --     --
  Treat. outcomes                                                                                                                                                                                      
      Cure                                                 166             69.8         (64.8--76.5)   19   45.2   (29.5--60.9)   6    35.2   (10.0--60.6)    5    38.5    (7.9--69.1)    185   66.7   (61.2--72.4)
      Default                                              50              21.3         (16.0--26.5)   9    21.4   (8.5--34.4)    5    29.4   (5.3--53.5)     3    23.1    (3.4--49.5)    59    21.2   (16.4--26.1)
      Transfer                                             3               1.3          (0.0--2.7)     2    4.8    (1.9--11.5)    1    5.9    (0.0--18.3)     1    7.7     (0.0--24.4)    5     1.8    (0.2--3.3)
      Failure                                              1               0.4          (0.0--1.3)     7    16.7   (4.9--28.4)    1    5.9    (0.0--18.3)     3    23.1    (0.0--49.6)    8     2.8    (0.9--4.9)
      Ongoing                                              1               0.4          (0.0--1.3)     0    0.0    (0.0--0.0)     0    0.0    (0.0--0.0)      0    0.0     (0.0--0.0)     1     0.4    (0.0--1.0)
      Death                                                14              5.9          (2.9--9.0)     5    11.9   (1.7--22.1)    4    23.5   (1.0--46.0)     1    7.7     (0.0--24.4)    19    6.8    (3.9--9.8)
      Not reported                                         3               --           --             0    --     --             0    --     --              0    --      --             3     --     --
      Not notified[^b^](#t005fn003){ref-type="table-fn"}   18              --           --             1    --     --             0    --     --              1    --      --             19    --     --
  No. of treatments after the survey period (relapse)                                                                                                                                                  
      One                                                  32              13.5         (9.1--17.9)    3    7.1    (0.0--15.3)    1    5.9    (0.0--18.3)     1    7.70    (0.0--24.4)    35    12.5   (8.6--16.4)
      Two                                                  5               2.1          (0.3--3.9)     3    7.1    (0.0--15.3)    0    0.0    (0.0--0.0)      3    23.08   (0.0--49.6)    8     2.9    (0.9--4.8)
      Three or more                                        4               1.7          (0.0--3.3)     0    0.0    (0.0--0.0)     0    0.0    (0.0--0.0)      0    0.00    (0.0--0.0)     4     1.4    (0.0--2.8)
      None                                                 196             82.7         (77.8--87.5)   36   85.7   (74.7--96.7)   16   94.1   (81.6--100.0)   9    69.23   (40.2--98.3)   232   83.1   (78.7--87.6)
      Not reported                                         19              --           --             1    --     --             0    --     --              1    --      --             20    --     --
  Total                                                    256                                         43                         17                          14                          299          

DR-TB, drug-resistant tuberculosis; MDR-TB, multidrug-resistant tuberculosis; TB, tuberculosis.

^a^ Percentages were calculated using the number of reported cases (i.e., the total number of cases minus the number of unreported cases) as the denominator.

^b^ Patients not found in the Brazilian Ministry of Health Notifiable Diseases Information System (SINAN) for TB and AIDS.

Regarding anti-TB treatment outcomes, cure was achieved in 66.7% of patients, and the default rate was 21.2% ([Table 5](#pone.0160109.t005){ref-type="table"}). None of the patients with DS-TB or DR/MDR-TB was treated with directly observed therapy (DOT). There was a negative association between cure and presence of DR and monoresistant TB (*p* \< 0.001). Overall, 16.9% of cases had at least one relapse. There was a trend toward a higher number of relapses among MDR-TB cases (30.7%) as compared with patients with other levels of drug resistance (17.3%) ([Table 5](#pone.0160109.t005){ref-type="table"}).

Discussion {#sec008}
==========

This study evaluated the clinical features and treatment outcomes of 299 TB cases identified in Porto Alegre through the II National Anti-Tuberculosis Drug Resistance Survey conducted in Brazil (2006--2007). The results indicate that two-thirds of the patients achieved sputum smear conversion at 2 months, but DR-TB and MDR-TB cases showed lower conversion rates than drug-sensitive TB cases. After a 3-year follow-up, the cohort showed a high overall relapse rate (16.9%), which was even higher among patients with MDR-TB (30.7%).

Sputum monitoring and culture conversion have been shown to be good indicators of treatment outcome in drug-sensitive TB, but those indicators have not been validated for MDR-TB \[[@pone.0160109.ref015]--[@pone.0160109.ref017]\]. Among MDR-TB patients, persistent positive sputum cultures at month 6 of treatment had a high negative predictive value for failure and relapse, but only a modest positive predictive value (\< 60%) \[[@pone.0160109.ref015],[@pone.0160109.ref016]\]. Following WHO recommendations \[[@pone.0160109.ref003]\], we used sputum conversion at month 6 of treatment of MDR-TB, which may be useful where health services have limited and/or delayed access to culture results. Horne et al. analyzed 20 studies where drug sensitivity testing (DST) was available, and found that both sputum-smear microscopy and mycobacterial culture during TB treatment have low sensitivity and modest specificity for predicting failure and relapse \[[@pone.0160109.ref015]\]. Brust et al. \[[@pone.0160109.ref018]\], evaluating a cohort of 56 patients with MDR-TB from a rural area of South Africa, found that the only independent predictor of culture conversion at 6 months was smear positivity.

The sputum conversion rate observed in the entire sample was considered good in view of the low rate of adherence to this strategy in Porto Alegre \[[@pone.0160109.ref019]\], despite the Brazilian Ministry of Health recommendation that sputum smear examination be performed monthly (or at least at 2, 4, and 6 months) in addition to monthly clinical monitoring of anti-TB treatment \[[@pone.0160109.ref008]\].

The high relapse rates observed are well above the Brazilian Ministry of Health estimate of 10% \[[@pone.0160109.ref008]\]. In addition, these rates are much higher than those reported in other nationwide studies involving drug-susceptible TB patients (Porto Alegre, 4.5%; Rio de Janeiro, 8.0%) \[[@pone.0160109.ref020],[@pone.0160109.ref021]\].

Also concerning was the high rate of default among patients with MDR-TB (23.1%). This rate is similar to that described by Tockzek et al. \[[@pone.0160109.ref022]\] when evaluating 10 studies in which directly observed therapy was not employed (26%).

Interruption of treatment may increase not only morbidity and mortality, but also the risk of transmission of resistant bacilli to healthy household members or even to institutionalized populations. As for cure, lower rates were found in patients with DR-TB and MDR-TB, which is consistent with the results reported in the literature \[[@pone.0160109.ref003],[@pone.0160109.ref005],[@pone.0160109.ref006],[@pone.0160109.ref022]\].

The study sample consisted mainly of white male young adults with low levels of education. These sociodemographic characteristics are similar to those reported in previous studies \[[@pone.0160109.ref004],[@pone.0160109.ref005],[@pone.0160109.ref023],[@pone.0160109.ref024]\].

Relatively high rates of smoking (55.1%), alcohol consumption (40.4%), and illicit drug use (26.3%) were observed in the current study. The Brazilian Ministry of Health estimates that over 20% of incident TB cases may be attributed to active smoking \[[@pone.0160109.ref011]\]. However, no evidence for an association of MDR-TB with smoking was found in the literature. The rate of alcohol consumption, although high, was similar to that reported in different regions of Brazil (Rio de Janeiro, 24.6%; Santa Catarina, 36.8%; Espírito Santo, 59.5%) \[[@pone.0160109.ref025]--[@pone.0160109.ref027]\] and in international series (South India, 29%) \[[@pone.0160109.ref028]\]. The literature suggests an association between TB and alcoholism, but evidence for an association between alcohol consumption and DR-TB is lacking \[[@pone.0160109.ref029]\]. Regarding illicit drug use, information on the relationship between injection drug use and DR-TB or MDR-TB is scarce \[[@pone.0160109.ref026],[@pone.0160109.ref030],[@pone.0160109.ref031]\]. In this study, these data were collected from patients' medical records, which precluded assessment of the actual number of patients who used inhaled or injected drugs for a proper comparison. Therefore, no association was identified with those variables, as risk associated to smoking, alcoholism and illicit drug use varies depending on use characteristics, and this information was not available.

As for comorbidities, a high rate of HIV infection was observed among patients with MDR-TB (30.0%). Studies have demonstrated that HIV infection increases the likelihood of anti-TB treatment failure, but there is still no consensus on the relationship between HIV infection and increased transmission of multidrug-resistant strains of *M*. *tuberculosis* \[[@pone.0160109.ref004],[@pone.0160109.ref032],[@pone.0160109.ref033]\]. No association was found between presence of diabetes and level of drug resistance, despite reports indicating that this comorbidity is more common in DR-TB cases \[[@pone.0160109.ref006],[@pone.0160109.ref034]\]. Although a higher frequency of chronic kidney disease was detected in DR-TB cases, the descriptive and exploratory nature of this research means we cannot provide confirmatory evidence for this association.

Despite the Brazilian Ministry of Health recommendation for directly observed therapy (DOT) as the standard of care for TB in Brazil \[[@pone.0160109.ref011]\], none of the patients with DS-TB or DR/MDR-TB was treated with DOT (data not shown). In addition, of 14 patients with MDR-TB, five (35.7%) came from hospitals (data not shown). Data from Porto Alegre Municipal Health Department epidemiological reports show that about 35% of patients who initiate anti-TB treatment come from hospitals \[[@pone.0160109.ref035]\], i.e., many patients use the emergency department as a point of entry into the TB control program. This is clearly not a desirable situation, because it is known that symptomatic patients who seek emergency care are often debilitated by prolonged illness, which increases the likelihood of transmitting drug-resistant strains in an environment without effective infection control measures.

Strengths of our study include: a) standardized screening of presumed DR-TB patients enrolled from eight public health care facilities (five primary health care units and three hospitals) in Porto Alegre; b) cultures and DST were performed at a reference laboratory that follows standard WHO guidelines; and c) the personnel performing cultures and DST were unaware of patients' clinical or radiographic findings.

The main limitations of this study are the nature of data collection, as most of the data were originally collected through the nationwide survey or extracted from medical records, and the fact that these data were not collected under clinical research conditions, in which all variables are usually controlled. Additionally, we relied on a small sample size of drug-resistant TB cases in the study period.

In summary, this study attempted to add to the existing literature by further exploring the clinical features of patients with pulmonary TB according to the level of drug resistance at a specific setting (Porto Alegre, capital of the state of Rio Grande do Sul, southern Brazil), focusing on treatment outcomes in patients treated in routine clinical practice. Patients with DR-TB and MDR-TB had lower 2-month sputum conversion and cure rates and more relapses than non-resistant TB cases. These data may be used as a surveillance indicator, as they reflect regional differences and the low effectiveness of the TB control program in this particular geographical setting, highlighting the need for DOT, especially among patients under retreatment.
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